Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

NCTID	NCT06458595 (View at clinicaltrials.gov)
Description	KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision. (Show More)
Indication	Neovascular (Wet) Age-Related Macular Degeneration
Compound Name	KH658
Sponsor	Chengdu Origen Biotechnology Co., Ltd.
Funder Type	Industry
Status	Not yet recruiting
Enrollment Count	44

Target Gene/Variant	Anti-VEGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Suprachoroidal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV
Editor Type
Dose 1	Undisclosed dose 1
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	1
Locations	China

Has US IND	False
Recent Updates